Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $2,060 | 1 | 52.2% |
| Food and Beverage | $943.00 | 11 | 23.9% |
| Travel and Lodging | $942.00 | 11 | 23.9% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Janssen Scientific Affairs, LLC | $2,410 | 5 | $0 (2018) |
| GENZYME CORPORATION | $612.13 | 7 | $0 (2019) |
| SANOFI-AVENTIS U.S. LLC | $481.45 | 6 | $0 (2017) |
| PFIZER INC. | $223.39 | 2 | $0 (2021) |
| Astellas Pharma US Inc | $172.09 | 2 | $0 (2021) |
| Janssen Biotech, Inc. | $45.56 | 1 | $0 (2019) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2021 | $222.70 | 2 | PFIZER INC. ($144.12) |
| 2019 | $520.48 | 6 | GENZYME CORPORATION ($381.41) |
| 2018 | $2,641 | 8 | Janssen Scientific Affairs, LLC ($2,410) |
| 2017 | $560.72 | 7 | SANOFI-AVENTIS U.S. LLC ($481.45) |
All Payment Transactions
23 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/03/2021 | Astellas Pharma US Inc | XTANDI (Drug) | Food and Beverage | In-kind items and services | $78.58 | General |
| Category: ONCOLOGY | ||||||
| 12/02/2021 | PFIZER INC. | XTANDI (Drug), ORGOVYX | Food and Beverage | In-kind items and services | $144.12 | General |
| Category: ONCOLOGY | ||||||
| 12/06/2019 | Astellas Pharma US Inc | XTANDI (Drug) | Food and Beverage | In-kind items and services | $93.51 | General |
| Category: ONCOLOGY | ||||||
| 12/06/2019 | Janssen Biotech, Inc. | Erleada (Drug) | Food and Beverage | In-kind items and services | $45.56 | General |
| Category: Oncology | ||||||
| 10/24/2019 | GENZYME CORPORATION | NO PRODUCT DISCUSSED (Drug) | Travel and Lodging | In-kind items and services | $159.79 | General |
| 10/24/2019 | GENZYME CORPORATION | NO PRODUCT DISCUSSED (Drug) | Food and Beverage | In-kind items and services | $126.84 | General |
| 10/24/2019 | GENZYME CORPORATION | NO PRODUCT DISCUSSED (Drug) | Travel and Lodging | Cash or cash equivalent | $83.28 | General |
| 10/24/2019 | GENZYME CORPORATION | NO PRODUCT DISCUSSED (Drug) | Travel and Lodging | Cash or cash equivalent | $11.50 | General |
| 12/12/2018 | Janssen Scientific Affairs, LLC | Erleada (Drug) | Consulting Fee | Cash or cash equivalent | $2,060.00 | General |
| Category: Oncology | ||||||
| 12/12/2018 | Janssen Scientific Affairs, LLC | Erleada (Drug) | Travel and Lodging | Cash or cash equivalent | $250.38 | General |
| Category: Oncology | ||||||
| 12/12/2018 | Janssen Scientific Affairs, LLC | Erleada (Drug) | Food and Beverage | In-kind items and services | $50.00 | General |
| Category: Oncology | ||||||
| 12/12/2018 | Janssen Scientific Affairs, LLC | Erleada (Drug) | Food and Beverage | In-kind items and services | $35.00 | General |
| Category: Oncology | ||||||
| 12/12/2018 | Janssen Scientific Affairs, LLC | Erleada (Drug) | Food and Beverage | In-kind items and services | $15.00 | General |
| Category: Oncology | ||||||
| 10/26/2018 | GENZYME CORPORATION | NO PRODUCT DISCUSSED (Drug) | Food and Beverage | In-kind items and services | $138.23 | General |
| 10/26/2018 | GENZYME CORPORATION | NO PRODUCT DISCUSSED (Drug) | Travel and Lodging | Cash or cash equivalent | $81.01 | General |
| 10/26/2018 | GENZYME CORPORATION | NO PRODUCT DISCUSSED (Drug) | Travel and Lodging | Cash or cash equivalent | $11.48 | General |
| 11/29/2017 | PFIZER INC. | SUTENT (Drug), INLYTA, TORISEL | Food and Beverage | In-kind items and services | $79.27 | General |
| Category: ONCOLOGY;RESPIRATORY | ||||||
| 10/07/2017 | SANOFI-AVENTIS U.S. LLC | NO PRODUCT DISCUSSED (Drug) | Travel and Lodging | Cash or cash equivalent | $176.15 | General |
| 10/07/2017 | SANOFI-AVENTIS U.S. LLC | NO PRODUCT DISCUSSED (Drug) | Food and Beverage | In-kind items and services | $136.89 | General |
| 10/07/2017 | SANOFI-AVENTIS U.S. LLC | NO PRODUCT DISCUSSED (Drug) | Travel and Lodging | Cash or cash equivalent | $15.35 | General |
| 10/07/2017 | SANOFI-AVENTIS U.S. LLC | NO PRODUCT DISCUSSED (Drug) | Travel and Lodging | Cash or cash equivalent | $10.50 | General |
| 10/05/2017 | SANOFI-AVENTIS U.S. LLC | NO PRODUCT DISCUSSED (Drug) | Travel and Lodging | In-kind items and services | $71.28 | General |
| 10/04/2017 | SANOFI-AVENTIS U.S. LLC | NO PRODUCT DISCUSSED (Drug) | Travel and Lodging | In-kind items and services | $71.28 | General |
About Paul Lange
Paul Lange is a Urology healthcare provider based in Seattle, Washington. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 10/27/2006. The National Provider Identifier (NPI) number assigned to this provider is 1780769596.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Paul Lange has received a total of $3,945 in payments from pharmaceutical and medical device companies, with $222.70 received in 2021. These payments were reported across 23 transactions from 6 companies. The most common payment nature is "Consulting Fee" ($2,060).
Practice Information
- Specialty Urology
- Location Seattle, WA
- Active Since 10/27/2006
- Last Updated 01/25/2013
- Taxonomy Code 208800000X
- Entity Type Individual
- NPI Number 1780769596
Products in Payments
- Erleada (Drug) $2,456
- NO PRODUCT DISCUSSED (Drug) $1,094
- XTANDI (Drug) $316.21
- SUTENT (Drug) $79.27
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Urology Doctors in Seattle
Dr. James Porter, M.d, M.D
Urology — Payments: $764,015
Cristopher Garlitz, M.d, M.D
Urology — Payments: $303,210
Dr. Thomas Walsh, M.d, M.D
Urology — Payments: $279,672
Marah Hehemann, M.d, M.D
Urology — Payments: $264,034
Una Lee, M.d, M.D
Urology — Payments: $131,923
Alvaro Lucioni, M.d, M.D
Urology — Payments: $57,879